{"contentid": 488482, "importid": NaN, "name": "Tecentriq approval on safer ground after FDA panel vote", "introduction": "While the US regulator has been taking a hard look at Accelerated Approvals which lack confirmatory data, Tecentriq (atezolizumab) appears set to retain its approval in breast cancer at least.", "content": "<p><span style=\"font-weight: 400;\">While the US regulator has been </span><a href=\"https://www.thepharmaletter.com/article/us-fda-tightens-ship-on-accelerated-approval-scheme\"><span style=\"font-weight: 400;\">taking a hard look</span></a><span style=\"font-weight: 400;\"> at Accelerated Approvals which lack confirmatory data, Tecentriq (atezolizumab) appears set to retain its approval in breast cancer at least.</span></p>\n<p><span style=\"font-weight: 400;\">The Oncologic Drugs Advisory Committee (ODAC) voted to maintain the decision on the basis of the clinically-meaningful benefit shown by the IMpassion130 study.</span></p>\n<p><span style=\"font-weight: 400;\">This is despite data from the IMpassion131 study failing to meet its primary endpoint on progression-free survival.</span></p>\n<p><span style=\"font-weight: 400;\">The combination of chemo plus Tecentriq, a checkpoint blocker from Swiss cancer giant Roche (ROG: SIX), has been marketed in this indication since early 2019.</span></p>\n<p><span style=\"font-weight: 400;\">Chief medical officer Levi Garraway explained: &ldquo;People with triple-negative breast cancer have few treatment options, which is why today's committee decision to recognise the importance of this Tecentriq combination is significant.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;We are grateful to the FDA and ODAC for the open dialogue and look forward to continued collaboration to improve the lives of people with breast cancer.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">While the opinion of the FDA&rsquo;s scientific panel is not binding, the agency usually opts to go along with the outcome.</span></p>\n<p><span style=\"font-weight: 400;\">On Wednesday the panel will move the conversation on to another of Tecentriq&rsquo;s Accelerated Approvals, this time as a treatment for people with locally-advanced or metastatic urothelial carcinoma.</span></p>\n<p><span style=\"font-weight: 400;\">Whereas the therapy was approved on the basis of Phase II data for this patient population, a subsequent Phase III study missed its primary endpoint.</span></p>", "date": "2021-04-28 13:41:00", "meta_title": NaN, "meta_keywords": "Tecentriq, cancer, data, breast, approval, Accelerated, Approvals, study, people, hard, panel, lack, confirmatory, regulator, atezolizumab, appears, retain", "meta_description": "While the US regulator has been taking a hard look at Accelerated Approvals which lack confirmatory data, Tecentriq (atezolizumab) appears set to retain its app", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-28 13:40:46", "updated": "2021-04-28 14:02:07", "access": NaN, "url": "https://www.thepharmaletter.com/article/tecentriq-approval-on-safer-ground-after-fda-panel-vote", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "tecentriq_big.png", "image2id": "tecentriq_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "Switzerland, USA", "company_tag": "Roche", "drug_tag": "Tecentriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-28 13:41:00"}